Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major ...

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

Asundexian (Bayer) significantly reduces the risk of ischemic stroke compared with placebo, without increasing the risk of ...

The trial met its main safety and efficacy endpoints in participants who experienced a non-cardioembolic ischemic stroke.

Asundexian is designed to reduce thrombus formation without increasing bleeding risk by selectively inhibiting FXIa.

Dr Chawla warns that stroke occur suddenly and explains how to recognise the warning signs, also known as Transient Ischemic Attacks.

Bayer’s asundexian meets primary efficacy and safety endpoints in landmark phase III OCEANIC-STROKE study in secondary stroke prevention: Berlin Tuesday, November 25, 2025, 11:0 ...

Bayers experimental stroke treatment, asundexian, delivered strong results in the Phase III OCEANIC-STROKE trial, prompting ...

A research paper by scientists at the Capital Medical University evaluated sex differences in stroke recurrence among ...

A mini stroke acts like the first warning signal of the body - it is an urgent notification that should never be overlooked – ...

Investing.com -- Bayer’s (ETR:BAYGN) experimental stroke drug could generate €3 billion in annual sales after successful trial results that Goldman Sachs analyst James Quigley called "transformational ...